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Abstract
Background: Progression-free survival (PFS) has been adopted as the primary endpoint in
many randomized controlled trials, and can be determined much earlier than overall survival
(OS). We investigated whether PFS is a good surrogate endpoint for OS in trials of first-line
treatment for epithelial ovarian cancer (EOC), and whether this relationship has changed with
the introduction of new treatment types.
Methods: In a meta-analysis, we identified summary data [hazard ratio (HR) and median
time] from published randomized controlled trials. Linear regression was used to assess the
association between treatment effects on PFS and OS overall, and for subgroups defined by
treatment type, postprogression survival (PPS) and established prognostic factors.
Results: Correlation between HRs for PFS and OS, in 26 trials with 30 treatment comparisons
comprising 24,870 patients, was modest (r2 = 0.52, weighted by trial sample size). The
correlation diminished with recency: preplatinum/paclitaxel era, r2 = 0.66; platinum/paclitaxel,
r2 = 0.44; triplet combinations, r2 = 0.22; biologicals, r2 = 0.30. The median PPS increased
over time for the experimental (Ptrend = 0.03) and control arms (Ptrend = 0.003). The difference
in median PPS between treatment arms strongly correlated with the difference in median
OS (r2 = 0.83). In trials where the control therapy had median PPS of less than 18 months,
correlation between PFS and OS was stronger (r2 = 0.64) than where the median PPS was
longer (r2 = 0.48).
Conclusions: In EOC, correlation in the relative treatment effect between PFS and OS in
first-line platinum-based chemotherapy randomized controlled trials is moderate and has
weakened with increasing availability of effective salvage therapies.

Keywords: chemotherapy, clinical trials, ovarian cancer, therapy
Received: 30 March 2017; revised manuscript accepted: 24 April 2018.

Introduction
Epithelial ovarian cancer (EOC) remains a
highly lethal disease, despite improvements in
treatment over the last three decades that have
increased the median survival but not the proportion of women cured.1 Most patients with
stage III disease relapse within 2 years after
debulking surgery and platinum-based chemotherapy, and more than half die within 5 years.2
There is an urgent need to accelerate development of active new treatments.
journals.sagepub.com/home/tam

Overall survival (OS) has traditionally been
regarded as the gold standard primary endpoint
for phase III randomized controlled trials evaluating the efficacy of new treatments for EOC.3,4
Demonstrating an improvement in OS requires
trials to be larger, with longer follow up, and
hence more cost. Most patients now receive multiple postprogression treatments, including chemotherapy, biological-targeted therapies and
surgery, which can significantly confound and
dilute the effects of the investigational therapy on
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the OS endpoint,5 and could impede the development of new potentially active therapies.
Progression-free survival (PFS) can be determined earlier than OS and has potential both as
an independent, valid endpoint and a potential
surrogate for OS in certain circumstances. PFS is
unaffected by postprogression therapies and may
provide earlier evidence of efficacy of new treatments, which can expedite regulatory approval.
The consensus of the Gynaecological Cancer
InterGroup (GCIG), which includes 29 academic
international trials groups, was that while OS
remains the gold standard for demonstrating benefit in first-line trials, PFS assessed using validated assessment tools is a valid primary endpoint
for phase III trials of first-line therapies for ovarian cancer.6 Furthermore, the GCIG statement
recognizes that differences in OS may be increasingly difficult to demonstrate in first-line trials
given the availability of active therapies following
progression.
In patients with recurrent ovarian cancer, other
goals of treatment, including time to treatment failure, improvement in cancer-related symptoms and
delaying time to subsequent therapy, are important
in considering the benefit of new therapies, apart
from improvement in survival outcomes.
While recognizing that PFS may be a valid endpoint in its own right, it is of interest to consider
to what extent improving PFS would be expected
to translate to a benefit in OS at a trial level.
Furthermore, for future first-line trials in EOC,
the value of these survival endpoints for determining the benefit of new therapeutics remains
important. Evaluation of the surrogacy relationship between PFS and OS at a trial level will continue to have value in guiding future trial design.
Since previous work evaluating the relationship
between PFS and OS in first-line trials of EOC,7,8
multiple new trials have been conducted with
active agents subsequently available in clinical
practice. We therefore performed a new literature-based meta-analysis with the primary objective of quantifying the strength of the relationship
between the relative treatment effects on PFS and
OS in phase III randomized controlled trials of
first-line treatments for EOC. We further evaluated, as secondary objectives, the potential impact
of the increased availability and number of salvage therapies over time, the duration of PPS,
and the impact of known prognostic factors on
the relationship between PFS and OS.
2

Methods
Search strategy
We searched MEDLINE, EMBASE and the
Central Registry of Controlled Trials of the
Cochrane Library (1 January 1996–30 June 2012)
using search terms ‘ovarian neoplasms’ or ‘ovarian cancer/carcinoma’, ‘chemotherapy’ and ‘clinical trials’ (supplemental file S1). The search
strategy was limited to studies in humans and in
the English language. Conference proceedings,
references of relevant review articles, citations of
included studies, and trial cooperative-group
websites were hand searched.
Study selection
All randomized phase III trials of first-line therapy in patients with stages IC–IV EOC in which
the treatment and intervention arms contained a
platinum chemotherapy backbone were eligible
for inclusion. Trials that included planned interval debulking were allowed. Trials were required
to report relative treatment effects for both PFS
and OS. If these data were incomplete, trials
were still included if sufficient information could
be retrieved from published Kaplan–Meier
curves. Trials of maintenance therapies or highdose chemotherapy with stem cell rescue were
ineligible.
Availability of anticancer agents for recurrent
EOC over time
The timing of the availability of anticancer treatments for recurrent EOC was recorded as the
year of approval by the United States Food and
Drug Administration (US FDA) for any clinical
indication, as recorded on its website.9 Data were
collected only for treatments with demonstrated
activity in EOC10 that could potentially be used
for treatment of recurrent disease.
Data extraction
For each included trial, we extracted the trial
name, year of publication or conference presentation, summary statistics of clinicopathologic characteristics (stage, performance status, extent of
debulking), type, and median duration of chemotherapy per treatment arm. We also recorded the
number of patients who were randomized and
who progressed and died, for each treatment arm.
We extracted data for hazard ratios (HRs) and
95% confidence intervals (CIs), and median OS
journals.sagepub.com/home/tam
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Figure 1. PRISMA diagram/flow chart.

PRISMA, preferred reporting items for systematic reviews and meta-analyses.

and PFS durations. In some trials, where cases of
death from causes other than ovarian cancer were
censored observations, time to progression was
used as the surrogate endpoint instead of PFS. In
this review, we considered time to progression
and PFS as interchangeable endpoints, given that
most patients with advanced ovarian cancer survive beyond the first relapse.
Data on adjusted HRs were used in preference to
unadjusted HRs whenever both results were available. In cases where multiple publications of the
same trial were available, the results with maximum follow up were used. In trials where there
were more than two treatment arms, we obtained
the HRs and 95% CIs from the pairwise comparison between the experimental treatments against
a common control therapy, and we treated each
comparison independently. If HRs and CIs were
journals.sagepub.com/home/tam

not reported, they were estimated using the methods described by Parmar and colleagues.11
Data were extracted independently by two
authors (KS, SL), and discrepancies were resolved
by consensus. Preferred reporting items for systematic reviews and meta-analyses (PRISMA)
reporting guidelines were followed for applicable
items and the study selection process was summarized in a flow diagram (Figure 1).12 Publication
bias is not a major consideration for this analysis
and was not assessed.
Statistical analysis
Because a larger difference in treatment effect for
PFS (surrogate endpoint) is assumed biologically
to translate into a larger difference in OS (true
endpoint), a linear model was fitted by the use of
3
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ordinary least-squares regression. We inspected
residual versus predicted plots and performed
diagnostic tests for normality and heteroscedasticity (nonconstant error variance) to assess consistency with the assumptions of linear regression.
All analyses were performed unweighted and then
weighted by trial size.
We reported r2, the trial-level correlation coefficient, between PFS and OS, both unweighted
and weighted by trial size, as derived from the
regression models. Any r2 value of 0.72 or greater
was considered a strong correlation, and r2 from
0.49 to less than 0.72 was considered modest correlation.7 The 95% CIs of r2 values were obtained
by the bootstrap method with 1000 replications.
Subgroup analyses were also carried out for trials
that examined different treatment paradigms
from different eras: before the use of platinum or
paclitaxel as control therapies, when platinum
and taxanes were used as control therapies, and in
the trials exploring triplet therapies and biological
therapies. We also classified these trials into subgroups on the basis of the median distributions
according to the proportion of patients with different prognostic characteristics (stage, performance status, and extent of debulking). Sensitivity
analyses were performed to evaluate the extent to
which the relationship changed with differing
proportions of established baseline prognostic
factors.
We also tested for the correlation between the difference in median PPS of experimental versus
control treatment arms and the difference in
median OS. The median PPS of a treatment arm
was defined as the difference between the median
OS and the median PFS. The difference in the
median PPS between the treatment arms for trials
conducted at different times was examined by
classifying trials by the year of the first patient
accrual, or if this was not available, the year of the
first trial publication. Differences in associations
between the HR for PFS and the HR for OS were
also evaluated for PPS at the cutoff point of 18
months for the control therapy. This cutoff point
was chosen on the basis of a prior study of simulated data,13 which reported a strong correlation
for PPS less than 18 months and a moderate to
weak correlation for PPS of 18 months or longer.
We performed sensitivity analyses to examine the
impact on the overall results of excluding trials of:
(1) intraperitoneal treatment, given that participants
4

in these trials were likely to have complete surgical
debulking and hence an overall better prognosis;
and (2) biological therapies, as many trials in other
advanced cancers had shown a significant relative
PFS advantage but no OS difference.
Analyses used STATA, version 14 (StataCorp:
College Station, TX, USA)
Results
In total, 26 trials with 30 treatment comparisons
and comprising 24,870 patients were included
(Figure 1 and Table 1). Most of the patients in
these studies had advanced EOC (median of rates
for all treatment arms 72.5% stage III, 17% stage
IV). Overall, two studies14,15 contained multiple
comparisons among different experimental therapies and a common control arm. There were twotrials15,16 of biological therapies and another two
trials17,18 of intraperitoneal therapy. In total, seven
comparisons reported an improvement in PFS
(upper limit of the 95% CI for HR <1.00 or
reported p < 0.05) and four comparisons reported
an improvement in OS (Table 1). In five trials, at
least one HR was not reported and had to be calculated.19–23 One trial used time to tumour progression in place of PFS.19
Figure 2 is a plot of the HR for PFS versus the HR
for OS. The notable outlier was a trial comparing
cisplatin-paclitaxel with cisplatin-cyclophosphamide, the first to compare two platinum combinations and to include a platinum-taxane combination.
Both PFS and OS were significantly better in the
experimental arm.24 Another outlier trial compared
cisplatin-paclitaxel with carboplatin-paclitaxel, and
reported a nonsignificant difference between the
treatment arms for both PFS and OS.28 When all
trials were included the correlation between HRs
for PFS and OS was moderate (unweighted r2,
0.53, 95% CI 0.23–0.72; r2 weighted by sample
size, 0.52, 95% CI 0.30–0.67).
Data on PPS available from 22 treatment comparisons showed a trend to an increasing median
PPS over time for both the experimental (Ptrend =
0.03) and control arms (Ptrend = 0.003) [Figure
3(a)]. The difference in median PPS between
treatment arms strongly correlated with the difference in median OS [unweighted r2, 0.75; 95%
CI 0.36–0.92; r2 weighted by sample size, 0.83,
95% CI 0.58–0.92; Figure 3(b)]. Details of post
progression therapy were reported for five
trials.24,26,27,29,34,40
journals.sagepub.com/home/tam
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Table 1. 26 trials and 30 comparisons included in the analysis (including biologics).
Trial

Yeara

Treatment

n (per arm)

HR for PFS
(95% CI)

HR for OS
(95% CI)

Median PFS
(months)

Median OS
(months)

GOG 11124

1996

cis, cyclo

202

0.7b

0.6b

13.0

24.0

cis, tax

184

(0.5–0.8)

(0.5–0.8)

18.0

38.0

cis or carbo (5
cycles)

118

0.91c d

1.02

13.0

24.0

cis or carbo (8
cycles)

115

(0.71–1.16)c d

(0.76–1.35)c

14.0

25.0

cis, cyclo

77

1.2

1

26.0

37.0

carbo, cyclo

81

~e

~e

19.0

35.0

carbo

760

0.92

1

15.5

33.0

CAP

766

(0.81–1.04)

(0.86–1.16)

17.0

33.0

cisplatin

200

1.06b

0.99b

16.4

30.2

cis, tax

201

(0.86–1.3)

(0.80–1.23)

14

26.6

cis, tax

108

1.07

0.85

~e

30.0

carbo, tax

100

(0.78–1.48)

(0.59–1.24)

~e

32.0

IV (cis, tax)

227

0.78

0.81

22.2

52.2

IP (IP cis, IV carbo,
tax)f

235

(0.66–0.94)

(0.65–1.00)

27.9

63.2

cis, cyclo

338

0.81c

0.75

11.0

25.8

cis, tax

342

(0.68–0.95)

(0.63–0.9)

15.0

35.6

carbo or CAP

1364

0.93

0.98

16.1

35.4

carbo, tax

710

(0.84–1.03)

(0.87–1.1)

17.3

36.1

cis, tax (PT)

386

1.05

1.045

19.1

44.1

carbo, tax (TC)

397

(0.89–1.23)

(0.87–1.26)

17.2

43.3

cis, tax

400

0.88b

0.84b

19.4

48.7

carbo, tax

392

(0.75–1.03)

(0.70–1.02)

20.7

57.4

carbo, tax

538

0.97b

1.13b

14.8

36.0

carbo, docetaxel

539

(0.83–1.13)

(0.92–1.39)

15

35.0

carbo, tax

121

1.01c

1.04c

38.0

40.6

tax, carbo, alt, cis

126

(~e)

(~e)

39.0

38.6

IV (cis, tax)

210

0.80

0.75

18.3

49.7

IP (IP cis, IV cis, tax)f

205

(0.64–1)

(0.58–0.97)

23.8

65.6

North Thames
Ovary Group19

GOCA25

ICON226

GOG 13227

Danish
collaboration28

GOG114/ SWOG17

OV10 (updated)20

ICON329

AGO30

GOG 15831

SCOTROC32

HeCOG21

GOG17218

1997

1997

1998

2000

2000

2001

2003

2002

2003

2003

2004

2005

2006

(Continued)
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Table 1. (Continued)
Trial

Yeara

Treatment

n (per arm)

HR for PFS
(95% CI)

HR for OS
(95% CI)

Median PFS
(months)

Median OS
(months)

AGO OVAR33

2006

carbo, tax

635

0.95b

0.93b

17.9

51.5

TEC (carbo, tax,
epirubicin)

647

(0.83–1.07)

(0.81–1.08)

18.4

49.5

carbo, tax

650

0.97b

1.01b

18.5

44.5

carbo, tax, topotecan

658

(0.85–1.1)

(0.86–1.18)

18.2

43.1

carbo, tax (24 h)

140

1b

1.17b

12.36

29.88

carbo, tax (96 h)

140

(0.78–1.28)

(0.90–1.52)

12.6

30.48

carbo, tax

223

0.75

0.92c

13.25

37.97

cis, tax, doxorubicin

228

(0.6–0.93)

~e

18.13

44.33

carbo, tax C1–8

864

16

44.1

carbo, tax,
gemcitabine C1–8

864

16.3

44.1

16.4

44.2

15.4

40.2

15.4

39.6

GINECO/AGO/
OVAR-534

GOG 16235

HeCOG22

GOG 18214

2006

2007

2008

2009

carbo, tax ×8 plus
PLD C 1,3,5,7

carbo, topotecan
C1–4 carbo, tax C5–8

carbo, gemcitabine
C1–4 carbo, tax C5–8

AGO OVAR/
GINECO/NSGO36

NCIC/EORTC/
GEICO23

MITO-237

HCOG38

JGOG (updated)39

6

2010

2010

2011

2012

2012

862

861

861

1.03b

1.01b

(0.92–1.14)

(0.89–1.14)

0.98b

0.95b

(0.88–1.10)

(0.84–1.09)

1.07b

1.05b

(0.96–1.19)

(0.93–1.19)

1.04b

1.11b

(0.93–1.15)

(0.98–1.26)

carbo, tax (TC)

882

1.18

1.05

19.3

51.5

carbo, tax,
gemcitabine

860

(1.06–1.32)

(0.091–1.2)

17.8

49.5

cis, topotecan C1–4
carbo, tax C5–8

409

1.10c

1.08c

16.2

~e

carbo, tax C1–8

410

(0.94–1.28)

(0.93–1.27)

14.6

~e

carbo, tax

410

0.95

0.89

16.8

53.2

carbo, PLD

410

(0.81–1.13)

(0.72–1.12)

19.0

61.6

carbo, tax ×8 (CP8)

192

1.37b

1.21b

21.9

52.3

carbo ×8, tax ×4
(C8P4)

190

(1.05–1.8)

(0.93–1.56)

16.5

46.7

carbo, 3-weekly tax

319

0.75

0.79

17.5

~e

journals.sagepub.com/home/tam

KM Sjoquist, SJ Lord et al.
Table 1. (Continued)
Trial

Yeara

Treatment

n (per arm)

HR for PFS
(95% CI)

HR for OS
(95% CI)

Median PFS
(months)

Median OS
(months)

carbo, weekly tax

312

(0.62–0.91)

(0.63–0.99)

28.1

NR

carbo, tax + bev
(short)

625

0.91

11.2

38.7

14.1

39.7

Biological agents
GOG 21815

2011

(0.80–1.04)
carbo, tax + bev

623

0.72
(0.63–0.82)

ICON 716

2012

carbo, tax

764

0.87

17.4

NR

carbo, tax + bev

764

(0.77–0.99)

19.8

NR

aYear

of publication.
hazard ratio reported.
cHazard ratio extrapolated from available information.
dTime to tumour progression reported.
eResult not given or able to be extracted.
fTrials of intraperitoneal therapies. All treatments were given intravenously except where indicated.
alt, alternating; bev, bevacizumab; CAP, cyclophosphamide, adriamycin, and cisplatin; carbo, carboplatin; CI, confidence interval; cis, cisplatin;
cyclo, cyclophosphamide; HR, hazard ratio; IP, intraperitoneal; IV, intravenous; OS, overall survival; PFS, progression-free survival; PLD,
pegylated liposomal doxorubicin; PT, cisplatin/taxol; NR, not reached; tax, paclitaxel; TC, taxol/carbo; TEC, taxol/epirubicin/carbo.
bAdjusted

Figure 2. Correlation between hazard ratios for progression-free and overall survival (all trials). The linear
regression line is shown. The circles indicate the weighting according to trial size.

Correlations between HRs for PFS and OS varied
for different treatment eras (Figure 4): preplatinum/taxane (n = 8; unweighted r2, 0.61, 95% CI
0.01–0.90; r2 weighted by sample size, 0.66, 95%
CI 0.02–0.96), platinum/paclitaxel (n = 11;
unweighted r2, 0.44, 95% CI 0.01–0.77; r2
weighted by sample size, 0.44, 95% CI 0.01–0.77),

journals.sagepub.com/home/tam

triplet combination therapies (n = 7; unweighted
r2, 0.25, 95% CI 0.00–0.66; r2 weighted by sample
size, 0.22, 95% CI 0.00–0.66), and novel therapies
(n = 4; unweighted r2, 0.21, 95% CI 0.00–1.00; r2
weighted by sample size, 0.30, 95% CI 0.00–0.56)
Correlations between HRs for PFS and OS also
varied according to PPS.

7
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Figure 3. (a). Median postprogression survival by treatment arm over time. The lines show predicted
relationships in the experimental arm (solid line) and the control arm (dashed line). The weights according to
trial size are shown by squares in the experimental arm and circles in the control arm.
(b). Differences in median progression-free survival and median overall survival (months) between intervention
and control arms. The line shows the linear regression line and the circles show the weight according to trial size.

In trials (n = 8) where the median PPS was less
than 18 months with control therapy, the correlation was higher (unweighted r2, 0.55, 95% CI
0.01–0.98; r2 weighted by sample size, 0.64, 95%
CI 0.00–0.98) than those trials (n = 18) in which
the median PPS was at least 18 months
(unweighted r2, 0.59, 95% CI 0.32–0.85; r2
weighted by sample size, 0.48, 95% CI 0.14–0.71;
Figure 5).
In subgroup analyses, trials that included 10% or
more patients (median distribution of trial populations) with Eastern Cooperative Oncology
Group (ECOG) performance status ⩾2 had
stronger correlation between PFS and OS (n = 9;
unweighted r2, 0.79, 95% CI 0.12–0.76; r2
weighted by sample size, 0.76, 95% CI 0.14–0.74)

8

than trials with less than 10% performance status
⩾2 patients (n = 18; unweighted r2, 0.52, 95% CI
0.04–0.94; r2 weighted by sample size, 0.53, 95%
CI 0.04–0.94; Figure 6). When trials with more
patients with stage IV disease (18% or greater of
trial populations; median distribution of trial populations) were compared with those with fewer
patients (less than 18% of trial population with
stage IV disease), the correlations were similar (r2
weighted by sample size, 0.49 versus 0.48)
Table 2 lists the year of US FDA approval of anticancer agents with clinical activity in EOC. Since
paclitaxel was approved in 1992, the number of
active agents has almost doubled, expanding the
options for subsequent lines of therapies beyond
the initial trial therapy.
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Figure 4. Correlation between hazard ratios for progression-free and overall survival by treatment regimen
in different eras, weighted by sample size: (a) preplatinum/paclitaxel; (b) platinum/paclitaxel; (c) triplet
combinations; (d) biological and other novel therapies.
predicted linear relationship ------ ideal relationship.

Figure 5. Correlations between hazard ratios for progression-free and overall survival according to
postprogression survival. (a) Median postprogression survival less than 18 months. (b) Median postprogression
survival at least 18 months.
predicted linear relationship ------- ideal relationship  weights according to trial size.

In sensitivity analyses, excluding trials of intraperitoneal treatment (unweighted r2, 0.49, 95%
journals.sagepub.com/home/tam

CI 0.18–0.69; r2 weighted by sample size, 0.49,
95% CI 0.26–0.66), and trials of biological
9
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Figure 6. Correlations between hazard ratios for progression-free and overall survival according to the
proportion of patients with poor performance status. (a) Fewer than 10% of patients with Eastern Cooperative
Oncology Group performance status ⩾2; (b) 10% or more patients with Eastern Cooperative Oncology Group
performance status ⩾2.
predicted linear relationship ----- ideal relationship  weights according to trial size.

therapies (unweighted r2, 0.58, 95% CI 0.27–
0.77; r2 weighted by sample size, 0.58, 95% CI
0.32–0.76), did not change the overall results
significantly.
Discussion
For PFS to be useful as a surrogate endpoint at
trial level, a strong correlation between the relative
treatment effects on PFS and OS is required.41
Correlations between PFS and OS have been
stronger in studies examining a limited number of
EOC trials that included contemporary standard
platinum-based therapies, (r2 ranges from 0.8542
to 0.947) but not more recent trials, particularly
those including biological-targeted and other
novel therapies. Moreover, in two different trials
conducted almost 10 years apart, the median PPS
in EOC almost doubled in cohorts of patients
treated with the same therapy of carboplatin-gemcitabine.43,44 We sought to address this question
given its important implications for future trial
design, selection of endpoints, drug approvals by
regulatory bodies, and healthcare funding.41
In clinical trials of advanced EOC, there was only
a moderate correlation (r2 = 0.52) between the
treatment effects on PFS and OS. When the correlations were examined for different treatment
paradigms based on clinical trials conducted in
different eras, the strength of the relationship
between the HRs for PFS and OS was less for
more recent regimens. Our finding of a significant
10

trend to an increase in the median PPS over time
and a strong correlation (r2 = 0.83 (weighted))
between the relative effects of treatment on PPS
and OS supports the hypothesis that postprogression therapy can dilute the relationship between
PFS and OS. This analysis is limited by the inability to adjust for baseline characteristics in the
absence of individual patient data. It is therefore
best considered hypothesis generating, with the
aim of encouraging further research.
The results of this study differ from the findings of
earlier studies, which reported strong correlations
in relative treatment effect between PFS and
OS.7,42 One possible explanation for this difference might be changes in the definition of PFS
over time. Before 2000, World Health Organization
criteria45 or clinical progression criteria were used
to define disease progression in clinical trials. In
some of the earlier trials, a second-look laparotomy was planned,25,27 or was reported to have
occurred,28 and the extent to which the laparotomy findings influenced assessment of progression is unclear from published information. Since
then, new guidelines to evaluate the response to
treatment and to define progression using both
imaging and CA125 levels have been introduced
and widely adopted in EOC trials.46,47
It is more likely that the impact and greater availability of more effective salvage therapies explain
the dilution of the previously observed relationship between the relative effects of treatment on
journals.sagepub.com/home/tam
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Table 2. Available salvage therapies for recurrent ovarian cancer.
Name

Year US FDA first approved

Carboplatin

1989 (ovarian) – as paraplatin

Cisplatin

1978 (prior to 1984)

Paclitaxel

1992 (December)

Docetaxel

1996 (for breast cancer)

Gemcitabine

1998 (for lung cancer)

Liposomal doxorubicin

1995

Etoposide

1983

Topotecan

1996

Altretamine

1990

Capecitabine

1998 (breast, 2001 colorectal)

Cyclophosphamide

Prior to 1984

Ifosfamide

1988

Irinotecan

1998 (full, accelerated 1996)

Melphalan

Prior to 1984 (oral form)

Oxaliplatin

2002

Nab-paclitaxel

2012 (for non-small cell lung cancer)

Pemetrexed

2004

Vinorelbine

1988

Bevacizumab

2012 (ovarian)/ 2004 (non-small cell lung cancer)

Anastrozole

1996 (breast)

Letrozole

1998 (breast)

Leuprolide acetate

1985 (prostate)

Megestrol acetate

Prior to 1984

Tamoxifen

Prior to 1984 (1977)

US FDA, United States Food and Drug Administration

PFS and OS. Few of the trials included in this
study provided any details of postprogression
therapies or the proportion of patients who
crossed over to receive the active experimental
therapy at progression. Of all the included trials,
only a single study24 of the six published before
2000 showed a statistically significant benefit of
the experimental treatment over control for PFS.
In contrast, 6 trials or comparisons15,17,22,39,48 of
18 published after 2000 reported a statistically
journals.sagepub.com/home/tam

significant benefit in favour of the experimental
treatment.
The duration of PPS affects the relationship
between the relative treatment effects for PFS
and OS. Broglio and Berry13 used simulated data
to demonstrate that the probability of a statistical
significant difference in OS between treatment
arms lessens with increasing duration of PPS,
despite a statistical difference for PFS. Our results
11
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in EOC trials support the findings of Broglio and
Berry (Figure 3), although our results are limited
by reliance on events occurring following randomization, and should therefore be considered
exploratory.
It is possible that improved imaging modalities
and the increasing use of CA125 to define progression could result in earlier detection of disease recurrence and hence inflate PPS in the more
recently conducted trials. However, we do not
believe that these factors alone would account for
all the improvement in PPS. Availability of effective salvage therapies remains the most likely
explanation for the increased PPS over time. This
is supported by the differing results of two second-line studies conducted almost a decade apart,
the Oceans trial43 and the AGO-OVAR2.25
trial.44 Both had a carboplatin-gemcitabine arm.
The PFS with carboplatin-gemcitabine in the
AGO trial was 8.4 months and in the Oceans trial
it was 8.6 months, but the median OS was respectively 18.0 and 32.9 months. The eligibility criteria were very similar, but in the Oceans trial
patients had a median of 5 (range 1–14) lines of
subsequent treatment, which almost certainly
accounted for the significantly longer PPS after
second-line therapy.
Our hypothesis of the influence of salvage therapies diluting the relationship between relative
treatment effects on PFS and OS is further supported by sensitivity analyses of trials that
included a greater proportion of patients with an
ECOG performance status of 2. In trials with
10% or more patients with performance status
⩾2, PFS and OS correlated more strongly than in
those with less than 10%. We speculate that
patients with a poor performance status were less
likely to receive second-line salvage therapies, and
therefore the relationship between the relative
treatment effects on PFS and OS was not
compromised.
Our work has a number of limitations. Published
summary data, instead of individual patient data,
means analyses could not be adjusted for baseline
prognostic factors that affect OS or for the number and type of salvage therapies used after initial
disease progression. We were also unable to
examine the individual patient-level correlations
between PFS and OS, which would require individual patient data. Our work is limited to clinical
trials of platinum-based chemotherapies because
these treatments are considered optimal and
12

standard first-line therapy for advanced EOC.10
The result of this study might not be applicable to
trials of nonplatinum regimens.
This study has evaluated the relationship between
PFS and OS in first-line trials of EOC in the modern era and has demonstrated that the correlation
between treatment effects for PFS and OS has
weakened. We expect that this relationship will
continue to decline with the increasing availability
of treatment options, including crossover to the
active experimental treatment following disease
progression. Therefore, it is increasingly unlikely
future trials will demonstrate a relative improvement in treatment effect for OS with first-line therapy. Using OS as primary endpoint will require
larger, longer trials in order for first-line treatments
to demonstrate an OS benefit. The financial and
opportunity costs of such trials make this approach
largely infeasible. Other approaches include
designing trials so that crossover is not allowed but
recognizing that access to other salvage therapies
will still occur outside trials. Trials could also be
designed with standardized postprogression treatments49 and meta-analyses of trials with similar
class of agents could also be planned prospectively.
Furthermore, novel statistical approaches, such as
penalized Cox regression49 that incorporate external estimates of the impact of salvage therapies in
order to adjust and preserve the randomized comparisons between different treatment groups could
be considered. Finally, a measure of net clinical
benefit, such as quality-adjusted PFS,50 could be
considered for treatment recommendations, which
would be appropriate even if a relative advantage
of OS has not been demonstrated.
Our findings support the fifth GCIG consensus
statement,6 ENREF_5, which advocates the use
of PFS as the primary trial endpoint in first-line
trials of advanced EOC, but this approach does
have limitations. Unlike OS, PFS is more prone to
bias, and consequently strict definitions of progression and mandated intervals between imaging
studies in trials are essential.1,4 The value of PFS
as the primary endpoint continues to be an issue
of ongoing debate, and PFS should be supported
and underpinned by additional endpoints, such as
patient-reported outcomes, time to second disease
progression (PFS2), and time to first and second
subsequent treatments.1,41,51,52 Alternatively endpoints such as quality-adjusted PFS,50,53 which
represent a measure of net clinical benefit, could
be used as primary endpoints and for clinical decision making and regulatory approval. It is also
journals.sagepub.com/home/tam
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important to demonstrate no OS detriment if PFS
is used as the primary endpoint.
In conclusion, the relative treatment effects for
PFS and OS are moderately correlated in firstline trials using platinum-based chemotherapy for
advanced EOC. This relationship has weakened
with time and increasing availability of effective
salvage therapies.
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